Stockscreener 앱 받기
654.04
0.17%
1.13
시장 영업 전:
651.04
-3.00
-0.46%
전일 마감가:
$652.91
열려 있는:
$645.56
하루 거래량:
1.12M
Relative Volume:
1.05
시가총액:
$68.13B
수익:
$14.25B
순이익/손실:
$4.58B
주가수익비율:
15.66
EPS:
41.7701
순현금흐름:
$3.88B
1주 성능:
+13.61%
1개월 성능:
+16.64%
6개월 성능:
+14.96%
1년 성능:
-29.12%
1일 변동 폭
$643.91
$664.00
1주일 범위
$575.93
$664.00
52주 변동 폭
$476.49
$883.15
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
654.04 | 68.62B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.89 | 106.97B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.56 | 63.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
820.36 | 50.61B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.22 | 35.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-14 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Why Regeneron Pharmaceuticals Inc. stock is considered a top pickEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com
Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals - Insider Monkey
Biopharma stocks regain ground in Q3 but still lag major indexes - BioWorld MedTech
Citigroup Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $708.00 at Royal Bank Of Canada - MarketBeat
Regeneron receives FDA CRL, delaying Eylea HD sBLA approval - Eyes On Eyecare
Wells Fargo & Company Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Cantor Fitzgerald Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $740.00 - MarketBeat
Regeneron (REGN) Margin Compression Reinforces Cautious Community Narratives Heading Into Earnings Season - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $865.00 at Guggenheim - MarketBeat
In a $1B+ deal, Modex joins with Regeneron to develop antibodies - BioWorld MedTech
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
Can Regeneron Pharmaceuticals Inc. stock maintain operating marginsTrade Exit Report & Verified Swing Trading Watchlists - newser.com
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewswire Inc.
Regeneron (REGN) Margin Dip Underscores Market Caution Despite Strong Relative Valuation - simplywall.st
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Evergreen Wealth Management LLC - MarketBeat
Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendations - newser.com
Using fundamentals and technicals on Regeneron Pharmaceuticals Inc.Profit Target & Risk Controlled Stock Alerts - newser.com
Wealthfront Advisers LLC Sells 1,560 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by AlphaQuest LLC - MarketBeat
Why millennials buy Regeneron Pharmaceuticals Inc. (RGO) stockJuly 2025 PostEarnings & AI Driven Stock Price Forecasts - newser.com
Why Regeneron Pharmaceuticals Inc. (RGO) stock is a strong buy callWeekly Trade Report & Free Safe Capital Growth Stock Tips - newser.com
News impact scoring models applied to Regeneron Pharmaceuticals Inc.Fed Meeting & Daily Oversold Bounce Ideas - newser.com
What MACD signals say about Regeneron Pharmaceuticals Inc.July 2025 Rallies & Low Drawdown Momentum Ideas - newser.com
Combining price and volume data for Regeneron Pharmaceuticals Inc.Market Performance Report & Long-Term Capital Growth Strategies - newser.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to Issue $0.88 Quarterly Dividend - MarketBeat
Regeneron receives another CRL for its Eylea 8 mg - Ophthalmology Times
Regeneron's Portfolio Still Supports a Narrow Moat Despite Competitive Threats to Eylea - Morningstar
REGN Receives Analyst Rating Boost with New Price Target | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (REGN) Sees Revised Price Target by RB - GuruFocus
Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback (REGN) - Seeking Alpha
Regeneron’s Aflibercept Study Sheds Light on Retinal Vasculitis Incidence - TipRanks
Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher? - Barron's
Market Starting To Embrace The 'New' Regeneron (NASDAQ:REGN) - Seeking Alpha
Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies - Fierce Biotech
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Up Following Earnings Beat - MarketBeat
Wells Fargo Raises Regeneron (REGN) Price Target Amidst Equal-We - GuruFocus
Regeneron teams up with Gary Nabel’s ModeX on multispecifics - Endpoints News
Cantor Fitzgerald Boosts Price Target for Regeneron Pharmaceuticals (REGN) | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Earnings Results, Beats Estimates By $2.10 EPS - MarketBeat
Guggenheim Raises Regeneron Pharmaceuticals (REGN) Price Target to $865 | REGN Stock News - GuruFocus
Regeneron Partners With ModeX Therapeutics To Discover And Develop Multispecific Antibodies - Nasdaq
FDA Formally Rejects Regeneron’s Eylea HD Over Manufacturing Issues - BioSpace
FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes - Yahoo Finance
Regeneron Pharmaceuticals (REGN) Analyst Rating Update: Price Ta - GuruFocus
RBC Raises Price Target on Regeneron Pharmaceuticals to $708 From $704, Keeps Sector Perform Rating - MarketScreener
Opko Health’s ModeX enters license, collab agreement with Regeneron - TipRanks
FDA rejects Regeneron’s Eylea HD amid filling facility woes - Pharmaceutical Technology
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2025 Earnings Call Transcript - Insider Monkey
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications - Yahoo Finance
What data driven models say about Regeneron Pharmaceuticals Inc.’s futureJuly 2025 Rallies & Real-Time Volume Analysis - newser.com
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.65%
16.33%
자본화:
|
볼륨(24시간):